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Crossed affino im m unoelectrophoresis  using  conca- 
navalin  A and Aleuria auran tia  lectin  as d iantennary  
glycan- and fucose-specific  affinocom ponents, resp ec­
tively, w as applied  to study ch an ges  in the con cen tra ­
tion and g lycosylation  of the acute phase protein  <*,- 
acid  g ly co p ro te in  (AGP) in sera  ob ta in ed  from pa­
tien ts  w ith  hyperim m unoglobu linem ia  D and periodic  
fever  syndrom e. In creases  in con cen tration  o f AGP 
com pared to control va lues w ere  found not only dur­
ing attacks, but also during rem issions. Compared to 
healthy  controls, the presence  of d iantennary  glycan- 
con ta in in g  glycoform s o f AGP also increased  during  
febrile attacks, w h ile  no ch an ges  w ere found during  
rem issions. A con tin u ou s high degree of a l —» 3 fuco- 
sylation  w as accom panied  by a continuous high ex ­
pression  of sialyl Lewis* on AGP. D espite  the clinical  
picture of recurrent febrile  attacks w ith  asym ptom at­
ic intervals, th ese  stu d ies  ind icate  that hyperim m uno­
globulinem ia  D should  be considered  a condition  of
p ersisten t inflam m ation. © 1995 A cad em ic  P re ss ,  Inc.
IN T R O D U C T IO N
Hyperimmunoglobulinemia D and periodic fever (hy­
per IgD syndrome)1 is a syndrome characterized by 
recurrent febrile attacks, usually of very early onset 
(during the first year of life) and a constantly elevated 
polyclonal serum IgD level. Since the first description 
of the hyper-IgD syndrome (1), the diagnosis has been 
made in up to 56 patients mainly from Europe in a 
collaborative study by the Hyperimmunoglobulinemia 
D Study Group (2-4). The attacks are characterized by 
an acute onset of high spiking fever, often preceded by 
cold chills. Abdominal complaints, vomiting, diarrhea,
1 Abbreviations used in this paper: AAL, Aleuria aurantia  lectin; 
Con A, concanavalin A; AGP; q,-acid glycoprotein; CAIE, crossed 
affinoimmunoelectrophoresis; SLeX, sialyl Lewis X; hyper-IgD syn­
drome, hyperimmunoglobulinemia D; ESR, erythrocyte sedim enta­
tion rate; CRP, C-reactive protein; AT, a ,-antitrypsin; IL-1, in terleu­
kin 1; IL-6, interleukin-6; TNF, tum or necrosis factor.
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headache, and arthralgias are associated with the ep­
isodes. During the attacks, swollen, tender lymph 
nodes are often found. Especially in the young age 
group, splenomegaly may be found. Nondestructive re­
current arthritis can be demonstrated in more than 
60% of the patients (4). During the attacks, most pa­
tients have skin lesions due to cutaneous vasculitis (3). 
Typical attacks occur every 4 to 8 weeks and last 3 to 7 
days each. Laboratory testing during attacks reveals 
an acute phase response (leukocytosis, neutrophilia, 
and increasing erythrocyte sedimentation rate (ESR)). 
The diagnosis is based on the clinical picture and the 
elevated serum IgD level (>100 U/ml). The pathogene­
sis of the syndrome remains to be elucidated and no 
treatm ent is known.
During remissions the concentration of C-reactive 
protein, a well-known marker of an acute phase reac­
tion, returns to normal levels, although it is elevated 
during attacks (4). It is unclear as yet whether the 
syndrome is characteristic for an acute state of inflam­
mation, or whether there is a state of persistent inflam­
mation. It has been shown in several types of inflam­
mation that the glycosylation of acute phase proteins 
changes during acute and chronic inflammatory pro­
cesses (5). a j-Acid glycoprotein (AGP, orosomucoid) is a 
positive acute phase protein with five N-linked glycans. 
At least 12 glycoforms of AGP can be detected in nor­
mal human serum differing in degree of branching, fu- 
cosylation, and sialylation of the glycans. The glyco­
forms containing one or more diantennary glycans are 
increased in concentration during acute inflammation. 
This occurs after acute traum a (6-9) or can appear 
with intercurrent infections, as have been described in 
rheumatoid arthritis (10, 12). In chronic inflammation 
such as rheumatoid arthritis , however, only minor 
changes could be established (10, 11). Cytokines like 
IL-1, IL-6 , and TNF are involved in the inflammatory 
response and have been shown to affect the glycosyla­
tion process in the liver (12-14). Besides the changes in 
diantennary glycan content, we have recently reported
0090-1229/95 $12.00 
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increases in the a l  —» 3 fucosylation of AGP, during 
both acute (15) and chronic inflammation (16, 17). The 
high degree of a l  —> 3 fucosylation in patients with 
rheumatoid arthritis could be returned to a lower level 
by means of treatm ent with methotrexate (17). This 
increase in fucosylation has also been described for 
haptoglobin (17-19) and -antitrypsin (AT) (17). The 
increased a l  —> 3 fucosylation was accompanied by an 
increased expression of blood group determ inant sialyl 
Lewisx (SLeX; NeuAca2 —> 3Gal01 —> 4 (Fucal —> 3)- 
GlcNAc-R) (16). Therefore, the type of glycosylation of 
the acute-phase protein AGP can give more informa­
tion about the state of inflammation and can serve as a 
better marker for discrimination between acute and 
chronic inflammatory states than the CRP concentra­
tion alone.
To gain a better understanding of the nature of the 
inflammatory response occurring in the hyper-IgD syn­
drome, the serum concentration of the acute-phase pro­
tein AGP and its type of glycosylation including the 
expression of SLeX were investigated in sera from pa­
tients with this syndrome, during both febrile attacks 
and remissions. Crossed affinoimmunoelectrophoresis 
(CAIE) was used to determine the presence of dianten- 
nary containing glycoforms of AGP using concanavalin 
A (Con A) as affinocomponent in the first-dimension 
gel. The presence of glycoforms with a l  —> 3 fucosy- 
lated glycans was determined using CAIE with Aleuria 
aurantia lectin (AAL) as affinocomponent. AAL is the 
only lectin to date tha t will react with the fucosylated 
lactosamine units present on AGP (15, 20, 21).
MATERIALS AND METHODS
Source o f sera. Eleven patients (nine males, two fe­
males) suffering from the hyper-IgD syndrome were 
studied. The diagnosis was in accordance with the 
guidelines of the “In terna tional Hyper-IgD Study 
Group," and these patients represented the numbers 2 ,
5, 9, 11, 18, 21, 24, 26, 27, 35, and 36 in a recent clinical 
review (4). The mean age at the time of the attacks and 
collecting of blood was 30 years (range 13-69 years) 
and all patients were Dutch. Sampling of serum was 
performed during attacks and remissions. Attacks 
were defined when the patients were febrile >38°C (not 
caused by infection) and experiencing symptoms com­
patible with the hyper-IgD syndrome. Remission was 
defined as the complete absence of symptoms for at 
least 2 weeks. No medical treatm ent was allowed dur­
ing the study period. In addition, sera from two pa­
tients suffering from the hyper-IgD syndrome, who had 
been asymptomatic for at least 2 years, were studied. 
Sera were stored at -20°C until analysis. Sera from 
healthy individuals were used for the determination of 
control values.
(Glyco)protein concentration. Concentrations of 
CRP were determined by rocket immunoelectrophore­
sis according to Laurell (2 2 ), using rabbit anti-human 
CRP IgG (RAH-CRP-IgG) for precipitation. AGP con­
centrations were determined by single radial immuno­
diffusion, according to Mancini et al. (23), using mono- 
specific anti-human AGP IgG (RAH-AGP-IgG) for pre­
c ip ita tio n . All an tib o d ie s  w ere p u rch ased  from 
Dakopatts, Glostrup, Denmark. Human serum C-reac- 
tive protein (HS-CRP) calibrator, consisting of a delip- 
idated pool of human serum enriched in CRP, was used 
as a standard for the determination of the CRP con­
centration; according to the m anufacturer’s informa­
tion the CRP concentration in this preparation was 
0.162 mg/ml. Human serum protein calibrator (HSPC), 
consisting of pooled sera from healthy blood donors, 
was used as a standard for the determination of the 
AGP concentration; according to the m anufacturer’s 
information tha t AGP concentration in this prepara­
tion was 0.76 mg/ml. Both HSPC and HS-CRP calibra­
tor were from Dakopatts.
Crossed a ff ino in in iunoelec trophoresis  {CAIE) .  
CAIE was performed according to the method of B0g- 
Hansen (24), using 2.5 mg/ml (with a hemagglutina­
tion titer of 512) Aleuria aurantia lectin (AAL) as the 
fucose-specific affino component, or 2 mg/ml concanav­
alin A as the diantennary-specific affinocomponent as 
described previously (15). AAL was isolated from fruit­
ing bodies of the Aleuria aurantia mushroom as de­
tailed earlier (15). In short, 0.5-2.0 fi\ of serum was 
electrophoresed through a lectin containing 1% aga­
rose gel, resulting in a separation of the differently 
glycosylated AGP forms. In the second, perpendicular 
dimension, these glycoprotein forms were immunoelec- 
trophoresed against the precipitating monospecific an­
tiserum (RAH-AGP-IgG). The resulting precipitation 
curves were visualized by staining with Coomassie 
brilliant blue R250 (Sigma, St. Louis, MO). The areas 
under the curves indicate the relative amounts of gly­
coprotein, which were determined using a Summa- 
graph (ACECAD D-9000) coupled to a 386 SX PC 
equipped with an area measurement program (devel­
oped by D. Philips, Department of Physiology, Faculty 
of Medicine, Vrije Universiteit, Amsterdam, The N eth­
erlands).
Partial purification of AGP from serum and detection 
of SLeX-content o f AGP. In order to obtain prepara­
tions enriched with AGP for a better interpretation of 
immunoblots, AGP was isolated from serum by immu- 
noaffinity chromatography, as described (25), using an 
anti-AGP-Sepharose 4B column. Serum (75-100 ¡i\) 
was applied to the anti-AGP-Sepharose 4B column (0.8 
x 1.3 cm; 2 ml/hr). The glycosylation profiles of AGP 
before and after affinity purification were identical, in­
dicating tha t no glycosidases were present during the 
procedure. The concentration was determined by ra ­
dial immunodiffusion, according to Mancini et al. (23). 
Ten percent SDS-PAGE was performed according to
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Laemmli (26) using the Mini Protean II dual slab gel 
apparatus from Bio-Rad. Gels were loaded with equal 
amounts of partially purified AGP; AGP isolated from 
Cohn fraction V from pooled normal human serum, a 
kind gift from Dr. D. H. van den Eijnden, was used as 
a standard. Proteins were blotted onto nitrocellulose by 
electrophoretic transfer using the Mini Transblot Cell 
from Bio-Rad. SLeX determinants on AGP were de­
tected as previously described (15) by incubating AGP 
containing nitrocellulose strips with mouse monoclonal 
anti-SLeX IgM [CSLEX-1 (27) 25 jug/ml in 10 times 
diluted PBS; ATCC HB8580], followed by alkaline 
phosphatase-conjugated goat anti-mouse IgM (1:250 
dilution, Zymed, San Francisco, CA) for detection. An 
AAL-nonreactive fraction isolated from pooled normal 
human serum by means of preparative affinity electro­
phoresis (25) was used as a negative control.
Statistics. All values were tested for significance 
using the Student t test.
RESULTS
Concentrations of CRP and AGP in hyper-IgD sera. 
The CRP concentrations in the sera of hyper-IgD pa­
tients were below 0.02 mg/ml during remission and 
increased to 0.10-0.30 mg/ml during an attack. In con­
trast, the AGP concentrations during remission were 
higher than those in control sera (1.98 mg/ml compared 
to 0.79 mg/ml in control sera, P < 0.05), with large 
interindividual differences. These concentrations in­
creased to an average value of 2.31 mg/ml during a 
febrile attack, also with large interindividual differ­
ences (Table 1). For the two patients who had been 
asymptomatic for at least 2 years, all protein concen­
trations had returned to control values (results not 
shown).
Reactivity o f AGP with Con A and AAL. To estab­
lish whether changes in the diantennary glycan con­
tent and q1 —> 3 fucosylation of AGP occurred in the 
sera of patients with the hyper-IgD syndrome during 
remission and febrile attacks, CAIE was performed 
with Con A and AAL as affinocomponents, respec­
tively. In Figs. lb, lc, le, and If, precipitation curves of 
AGP are illustrated for one hyper-IgD patient, pro­
duced by CAIE with Con A and AAL, respectively. Dur­
ing a febrile attack, the reactivity with Con A was sig­
nificantly increased compared to control and remission 
values (P < 0.05), since the percentage of the Con A 
nonreactive fraction (CO) was decreased from 40.6% 
during remission to 35.3% during an attack (Table 1). 
The degree of reactivity ((C2 + C3)/C1) was concomi­
tantly increased from 0.37 during remission to 0.51 
during an attack. During remission, the reactivity of 
AGP with Con A returned to the control value (Ta­
ble 1).
The reactivity of AGP with AAL showed more dis­
tinct differences when compared to control values for 
both states of disease (Table 1). The degree of reactivity 
((A3 + A4 + A5)/(A1 + A2)) of AGP with AAL for hy­
per-IgD patients was extremely high during both a fe­
brile attack (3.64) and remission (3.51). Although the 
values expressed large interindividual differences, 
they were significantly different from the degree of 
AAL reactivity of the control (0.92, P < 0.05). These 
increases in degree of reactivity corresponded with low 
percentages of unreactive component (A0) for AGP dur­
ing both remission (16.6%) and fever (15.8%) compared 
to the control value (38.0%). The glycosylation of AGP 
m the sera from patients who had been asymptomatic 
for at least 2 years had returned to control values, with 
respect to both the diantennary glycan content and the 
a l  —> 3 fucosylation (results not shown).
I f
Expression o f Sialyl Lewis' (SLeX) on AGP in hyper- 
IgD sera. In order to determine if the increases in a l  
—> 3 fucosylation also coincided with an increased ex­
pression of SLeX, partially purified AGP from 4 of the
TABLE 1














Control < 0.02 0.79 ±0.17 10 46.0 ±8.0 0.33 ±0.11 38.0 ± 13.0 0.92 ± 0.36
HIgD—remission < 0.02 1.98 ± 0.72“ 11 40.6 ± 5.6 0.37 ±0.10 16.6 ± 8 .2" 3.51 ±2 .17“
(11/0 ) (0/ 11) (7/4) (9/2) (1/ 10) (0/ 11)
HIgD—fever o . i s i o . i o "-6 2.31 ± 1.10" 11 35.3 ± 4.7a b 0.51 ± 0.15a’6 15.8 ± 8 .8“ 3.64 ± 2.06“
(0/ 11) (0/ 11) (2/9) (4/7) (3/8) (0/ 11)
Note. Values are given as the mean ± SD. DR, degree of reactivity; this is a measure for the intensity of the interaction between the lectin 
and AGP. The degrees of reactivity were determined by dividing the sum of the strongly reactive glycoforms by the sum of the moderately 
reactive glycoforms. CO and A0, fraction of AGP nonreactive with Con A and AAL, respectively. Values given in parentheses are the ratio of 
values th a t fall within the control range over the values th a t fall outside it.
“ Significantly different from control value P  < 0.05. 
b Significantly different from HIgD—remission value P  < 0.05.
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FIG . 1. Reactivity of AGP with Con A (a-c) and AAL (d-f) in 
control serum  (a,d) and hyper-IgD serum during remission (b,e) and 
during a febrile attack (c,f). Serum (0.5-2.0 ¿¿1) from the same patient 
was subjected to CAIE as described under M aterials and Methods. 
Only the second-dimension gels are shown. The lower right corner of 
each gel corresponds w ith  the  site  of application in the  first- 
dimension gel. Electrophoresis was performed in the directions right 
to left for the first dimension and bottom to top for the second di­
mension. CO and AO, AGP fractions th a t  are nonreactive with Con 
A and AAL, respectively; C1-C3 and A1-A5, forms of AGP th a t are 
increasingly reactive with Con A and AAL, respectively.
11 different patient sera (chosen at random) was sub­
jected to SDS-PAGE, blotted, and subsequen tly  
stained with a monoclonal antibody directed against 
SLeX (CSLEX-1). A representative Western blot of 
AGP isolated from one patient is shown in Fig. 2. Upon 
staining of AGP-containing nitrocellulose strips with 
CSLEX-1, a weak positive staining of AGP from sera 
obtained from healthy individuals was observed (Fig. 
2, lane 1). A strongly enhanced positive staining was 
observed for AGP isolated from hyper-IgD patients 
during remission and febrile attack (Fig. 2, lanes 3 and
4, respectively), indicating a significant increase in the 
expression of SLeX on AGP in the hyper-IgD syn-
! I
1 e  3  a
FIG . 2. Expression of SLeX on partially purified AGP from hy- 
per-IgD sera. Equal am ounts of affinity-purified AGP [3 \±g as de ter­
mined by radial immunodiffusion (23)] were subjected to SD S- 
PAGE, subsequent blotting, and detection of SLeX with a specific 
monoclonal antibody (CSLEX-1) as described under M aterials and 
Methods. A representative W estern blot of AGP from one hyper-IgD 
patien t is shown; only the part of the blot containing AGP bands is 
reproduced. 1, AGP from control serum; 2, AGP nonreactive with 
AAL; 3, AGP from hyper-IgD serum during remission; 4, AGP from 
hyper-IgD serum  during an attack.
drom e. No s ta in in g  was observed  for an AAL- 
nonreactive fraction isolated from the serum of healthy 
individuals (Fig. 2, lane 2), which was used as a nega­
tive control.
D ISC U SSIO N
Although the hyper-IgD syndrome is characterized 
by short febrile attacks followed by apparently asymp­
tomatic intervals, the present study is indicative of 
both acute and chronic inflammatory responses within 
this disease. The concentration of the acute phase pro­
tein AGP is significantly increased during both febrile 
attacks and remissions, as compared to concentrations 
in serum of healthy individuals. The concentration of 
CRP is increased only during febrile attacks. The a l  —> 
3 fucosylation of AGP, as indicated by the high reac­
tivity with AAL and the CSLEX-1 staining, in serum of 
hyper-IgD patients is increased during both attacks 
and remissions. The increases in al —> 3 fucosylation 
are extreme compared to the value for healthy individ­
uals, with a concomitant increased expression of SLeX. 
Previously, it has been shown that for chronic inflam­
mation such as rheumatoid arthritis, the percentage of 
nonfucosylated AGP (AO) was approximately 18 (17), 
whereas for acute inflammation induced by laparoto­
my, this percentage was found to be approximately 30 
(15). Therefore, the low percentages of nonfucosylated 
AGP (AO) continuously present in hyper-IgD patients 
are compatible with chronic inflammation. The contin­
uously high a l  —> 3 fucosylation in rheumatoid arth ri­
tis can be decreased by treatment with methotrexate, 
and this coincides with a decrease in disease activity 
(17). Possibly, the relatively high frequency of febrile 
attacks (once every 4-8 weeks) in the hyper-IgD syn­
drome does not allow the a l —> 3 fucosylation to return 
to a basic level, since after an asymptomatic period of 2 
years, the concentrations of CRP and AGP and the gly- 
cosylation of AGP returned to control values. This 
would be in agreement with our previous finding that 
in the case of severe burns, the a l — » 3 fucosylation can 
remain extremely high for at least 30 days after the 
event (15), indicating a persistent state of inflamma­
tion.
With respect to the Con A reactivity of AGP, signif­
icant increases occurred during a febrile attack, re­
turning to control values during remission. These in­
creases in Con A reactivity of AGP may be interpreted 
as increases in diantennary glycan content, since it has 
previously been shown that the glycans of AGP are of a 
complex type, in both healthy and diseased states (9). 
This supports the previous findings that the febrile a t­
tack is accompanied by an acute phase response, which 
is further corroborated by the steeply elevated CRP 
plasma concentrations found in these patients during 
attacks.
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In conclusion, our studies indicate that the hyper- 
IgD syndrome seems to be a disorder of persistent in­
flammation. On the one hand the concentration of AGP 
continuously increases during attacks and remissions, 
as does the a 1 —> 3 fucosylation of AGP, indicating a 
chronic state of inflammation. On the other hand the 
concentration of CRP increases only during attacks, as 
does the diantennary glycan content of AGP, indicating 
an acute state of inflammation within the persistently 
inflamed state. These patterns are also found during 
intercurrent infections in patients with rheumatoid a r­
thritis (11), but are unique for a noninfectious disorder 
like the hyper-IgD syndrome. Proinflammatory cyto­
kines (IL-1, IL-6, TNF) have been shown to modify the 
glycosylation of acute phase proteins such as AGP (12- 
14). The changes reported here for the hyper-IgD syn­
drome suggest a possible role for such cytokines in the 
pathogenesis of this syndrome.
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